CNS Pharma partners with MD Anderson
May 29, 2020 -- Cancer biopharmaceutical company CNS Pharmaceuticals has entered into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to investigate cancer treatment technologies.
Online tool tracks COVID-19 vaccine development
May 28, 2020 -- A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University of Notre Dame Center for Research Computing.
CordenPharma to provide excipients for Moderna's vaccine candidate
May 28, 2020 -- A supplier of active pharmaceutical ingredients, CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273.
Millipore, Baylor partnering on COVID-19 vaccine
May 27, 2020 -- MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership will help accelerate the vaccine candidates to phase I clinical trials.
EdiGene, Immunochina to develop CAR-T therapy
May 27, 2020 -- EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.
Ajinomoto to manufacture COVID-19 drug for Humanigen
May 27, 2020 -- Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19.
AbCellera raises $105M to fund antibody drug development
May 27, 2020 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity and more.
Merck to acquire Themis for SARS-CoV-2 vaccine
May 26, 2020 -- Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2.
Merck, Ridgeback Bio partner on COVID-19 antiviral
May 26, 2020 -- Merck and Ridgeback Biotherapeutics announced that they have entered a collaboration to develop EIDD-2801, an orally available antiviral candidate in early clinical development for treatment of patients with COVID-19.
Novasep, Lysogene partner for gene therapy
May 26, 2020 -- Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based gene therapy drug candidate (LYS-GM101) for the treatment of GM1 gangliosidosis, a neuronopathic lysosomal storage disorder.
Conferences
2nd Annual Cell Therapy Bioprocessing Conference
June 25-26
Boston, Massachusetts United States
BioProcess International Europe
July 13-16
Amsterdam, Noord-Holland Netherlands
Bioprocess International West
August 10-13
Santa Clara, California United States
General Discussion
Topic Replies / Views Last Update
https://academic.oup.com/ve/pages/coronavirus-evolution
by Michael
0 / 29 More than 3 days ago
by Michael
PopSci Hails Impossible Burger 2.0 as Most Important Engineering Innovation in 2019
by Mahesh Gupta
0 / 11 More than 3 days ago
by Mahesh Gupta
Engineered Bacteria Produces BeeFree Honey
by Mahesh Gupta
0 / 12 More than 3 days ago
by Mahesh Gupta
Consumers' Preference to Buy Unlabeled Produce Increases after Exposure to GMO-labeled Pro
by Mahesh Gupta
0 / 15 More than 3 days ago
by Mahesh Gupta
Super-precise new CRISPR tool could tackle a plethora of genetic diseases
by Mahesh Gupta
0 / 14 More than 3 days ago
by Mahesh Gupta
To see more posts from our community or to share a post of your own, go to our community's forum page.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter